Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Dermatology
•
Atopic Dermatitis
What criteria do you utilize in deciding between different jak inhibitors for atopic dermatitis?
Abrocitinib (cibinqo) vs upadacitinib (rinvoq)
Related Questions
How do you counsel families of pediatric patients on methotrexate about live vaccine schedules?
How do you weigh the risks/benefits of cytokine blockade (eg dupilumab) in pregnant patients?
When would you pursue genetic testing for severe recalcitrant atopic dermatitis?
What is the longest interval that you have been able to stretch a biologic before losing efficacy?
How do you manage atopic dermatitis in patients who have failed dupilumab?
Do you generally require preventative vaccination prior to initiating JAK inhibitor therapies?
What is your approach to managing moderate to severe atopic dermatitis in pregnancy?
Can Dupixent (dupliumab) be safely used in patients who are taking other biologics for rheumatic disease?
Do you have to remove gold dental crowns if patch testing reveals a gold allergy?
How do you decide between IL-4/IL-13 blockade (dupixent) versus IL-13 blockade only (Adbry) as treatments for Atopic Dermatitis?